IsoRay Inc - Entwickler von isotopbasierten Medizinprodukten
eröffnet am 28.10.20 23:37:41 von
neuester Beitrag 08.04.24 19:55:04 von
neuester Beitrag 08.04.24 19:55:04 von
Beiträge: 117
ID: 1.333.129
ID: 1.333.129
Aufrufe heute: 0
Gesamt: 8.357
Gesamt: 8.357
Aktive User: 0
ISIN: US46489V1044 · WKN: A0MQNM · Symbol: CATX
1,6900
USD
+6,96 %
+0,1100 USD
Letzter Kurs 21:01:56 AMEX
Meistbewertete Beiträge
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9700 | +324,79 | |
| 0,5640 | +23,44 | |
| 0,5700 | +23,38 | |
| 0,6300 | +21,39 | |
| 45,45 | +19,95 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5480 | -12,74 | |
| 1,3200 | -14,84 | |
| 0,5568 | -16,91 | |
| 0,6835 | -20,53 | |
| 1,8819 | -55,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
So die 1,50 soll wohl nicht fallen. Morgen die Teilnahem an der 3 Goldman Sachs Healthruption Conference und am 11 April auf der Jefferies Radiopharma. Mal sehen ob man hier weitere Investoren überzeugen kann.
Antwort auf Beitrag Nr.: 75.554.596 von Edelweiss70 am 02.04.24 22:53:17So dann mal auf in eine hoffentlich ereignisreiche und erfolgreiche Woche
Antwort auf Beitrag Nr.: 75.499.050 von Edelweiss70 am 22.03.24 08:25:00Herrlich 🎉. Das sieht doch sehr gut aus. Hier muss doch zeitnah was vermeldet werden, das ist doch mehr als ein Brodeln.
Danke Crowww, ich hoffe das ist erst der Anfang einer großen Story.
Auf das was da noch kommt …..
Auf das was da noch kommt …..
Glückwunsch Edelweiss 😍
Trading Spotlight
Antwort auf Beitrag Nr.: 75.496.794 von Edelweiss70 am 21.03.24 18:49:31Fast auf Tageshoch bei neuem 52Wochen Hoch geschlossen.
Stabil 💪
Stabil 💪
Antwort auf Beitrag Nr.: 75.473.016 von Edelweiss70 am 18.03.24 13:46:24So langsam geht ‘r d’r Peeeter 🐿.
Antwort auf Beitrag Nr.: 75.473.007 von Edelweiss70 am 18.03.24 13:45:41Der Kurs zieht vorbörslich ja schon ganz gut an , mal sehen was da geht
Antwort auf Beitrag Nr.: 75.433.719 von Edelweiss70 am 11.03.24 18:26:28
Globenewswire
18.3.24
Full article
„SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.
Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study. „
Globenewswire
18.3.24
Full article
„SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. The study has completed enrollment in the first cohort and has commenced dosing in the second cohort.
Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study. „
globalnewswire 11.3.24
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here.
The event will feature presentations from the following members of the Company’s management:
Thijs Spoor, Chief Executive Officer
Michael K. Schultz, PhD, Chief Science Officer
Markus Puhlman, MD, Chief Medical Officer
In addition, key opinion leader Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) will provide an overview of the use of specialized targeting peptides and personalized alpha-particle radiopharmaceuticals such as 212Pb to diagnose tumors and deliver powerful radiation specifically to cancer cells.
The event will highlight the Company's theranostic approach and proprietary technology, including the development of complementary imaging diagnostics that enable the ability to see the specific tumor and then treat it, to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.
A live question and answer session will follow the formal presentations.
About Richard L. Wahl, MD
Richard L. Wahl, MD, is a professor at Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis and served as the director of MIR from 2014 to 2023. An alumnus, Wahl completed a diagnostic radiology residency and nuclear medicine fellowship at MIR. Prior to being named director at MIR, he was director of the Division of Nuclear Medicine at Johns Hopkins University and the first recipient of the Henry N. Wagner Jr. Professorship.
Wahl is a leader in the use of PET scans to diagnose human cancers and other diseases and was among the first to harness the power of the immune system to precisely target radiation therapy to cancers, a technique that has become known as radioimmunotherapy. He has been at the forefront of efforts to combine quantitative data from multiple kinds of scans to form so-called fusion images that can help physicians more precisely diagnose and characterize cancers.
Wahl has received numerous awards, including the 2018 Georg Charles de Hevesy Award from the Society of Nuclear Medicine and Molecular Imaging, where he served as president. He is an elected member of the American Society for Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. A fellow of the American College of Radiology, Wahl holds 18 radiology patents and has published more than 450 peer-reviewed scientific manuscripts. He completed a research fellowship in immunology and earned his medical degree from Washington University in St. Louis.
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here.
The event will feature presentations from the following members of the Company’s management:
Thijs Spoor, Chief Executive Officer
Michael K. Schultz, PhD, Chief Science Officer
Markus Puhlman, MD, Chief Medical Officer
In addition, key opinion leader Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) will provide an overview of the use of specialized targeting peptides and personalized alpha-particle radiopharmaceuticals such as 212Pb to diagnose tumors and deliver powerful radiation specifically to cancer cells.
The event will highlight the Company's theranostic approach and proprietary technology, including the development of complementary imaging diagnostics that enable the ability to see the specific tumor and then treat it, to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.
A live question and answer session will follow the formal presentations.
About Richard L. Wahl, MD
Richard L. Wahl, MD, is a professor at Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis and served as the director of MIR from 2014 to 2023. An alumnus, Wahl completed a diagnostic radiology residency and nuclear medicine fellowship at MIR. Prior to being named director at MIR, he was director of the Division of Nuclear Medicine at Johns Hopkins University and the first recipient of the Henry N. Wagner Jr. Professorship.
Wahl is a leader in the use of PET scans to diagnose human cancers and other diseases and was among the first to harness the power of the immune system to precisely target radiation therapy to cancers, a technique that has become known as radioimmunotherapy. He has been at the forefront of efforts to combine quantitative data from multiple kinds of scans to form so-called fusion images that can help physicians more precisely diagnose and characterize cancers.
Wahl has received numerous awards, including the 2018 Georg Charles de Hevesy Award from the Society of Nuclear Medicine and Molecular Imaging, where he served as president. He is an elected member of the American Society for Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. A fellow of the American College of Radiology, Wahl holds 18 radiology patents and has published more than 450 peer-reviewed scientific manuscripts. He completed a research fellowship in immunology and earned his medical degree from Washington University in St. Louis.
Durchsuchen
